- Research article
- Open Access
Truncation in the tcdC region of the Clostridium difficilePathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A
BMC Infectious Diseases volume 9, Article number: 103 (2009)
The increased severity of disease associated with the NAP1 strain of Clostridium difficile has been attributed to mutations to the tcdC gene which codes for a negative regulator of toxin production. To assess the role of hyper-production of Toxins A and B in clinical isolates of Clostridium difficile, two NAP1-related and five NAP1 non-related strains were compared.
Sequencing was performed on tcdC, tcdR, and tcdE to determine if there were differences that might account for hyper-production of Toxin A and Toxin B in NAP1-related strains. Biological activity of Toxin B was evaluated using the HFF cell CPE assay and Toxin A biological activity was assessed using the Caco-2 Trans-membrane resistance assay.
Our results confirm that Toxin A and Toxin B production in NAP1-related strains and ATCC 43255 occurs earlier in the exponential growth phase compared to most NAP1-nonrelated clinical isolates. Despite the hyper-production observed in ATCC 43255 it had no mutations in tcdC, tcdR or tcdE. Analysis of the other clinical isolates indicated that the kinetics and ultimate final concentration of Toxin A and B did not correlate with the presence or lack of alterations in tcdC, tcdR or tcdE.
Our data do not support a direct role for alterations in the tcdC gene as a predictor of hyperproduction of Toxin A and B in NAP1-related strains.
Toxigenic Clostridium difficile causes C. difficile-associated diarrhea (CDAD) which is a predominant nosocomial infection in Canada as well as other countries [1–15]. In Manitoba, in 2008, there were 890 lab-confirmed cases of CDAD versus 535 total cases of infectious diarrhea due to all other bacterial enteric pathogens combined .
Recently published data indicates that although CDAD incidence varies by geographic region there is evidence that overall it is increasing [2, 4, 5, 7, 12–15, 17]. In Quebec there were 35.6 cases per 100,000 population in 1991 versus 156.3 cases per 100,000 in 2003 . The severity of infection as assessed by mortality rates has increased in certain geographic locations [2–4, 7, 8, 15, 18, 19]. The C. difficile strain designated NAP1 (equivalent to PCR ribotype 027) was the most prevalent strain associated with the Quebec outbreak of CDAD [4, 5, 7, 8, 15] and it has been found in other parts of Canada as well . The significant increase in incidence and disease severity reported for the Quebec outbreak have prompted investigations to determine if this strain has some unique virulence characteristics. This strain has the gene (cdtB) encoding binary toxin [4, 18, 21, 22] and this has been suggested to contribute to disease severity [15, 23, 24]. The tcdC gene is the putative negative regulator for toxin production within the pathogenicity locus (PaLoc) of C. difficile [3, 4, 15, 20, 25] and deletions in this gene have been suggested to affect the regulatory function and account for the apparent high levels of toxin production of the NAP1 outbreak strain [4, 20, 25]. The initial studies used in vitro ELISA to quantify the production of Toxin A and B relative to the growth curve for the a collection of NAP1 strains that were toxinotype III compared to the a collection of clinical isolates that were toxinotype 0 . Because there may be differences in the biological activity versus antigen detected, further data evaluating the biological levels of Toxins A and B are needed.
The objective of this study was to provide correlation between the kinetics of toxin production using functional assays and the growth kinetics of various clinical strains of C. difficile. The primary focus of this study was to evaluate the effects of the tcdC region deletions that have been described (18 bp and 1 bp deletions) on the kinetics of biologically active Toxin A and B production. This was done in the context of clinical isolates, thereby evaluating the role of this gene in the overall kinetics of toxin A and B production. Genetic analysis of the tcdR and tcdE regions was also performed to determine if deletions or mutations in these genes accounted for differences in toxin A and B production.
Eight strains of C. difficile were selected for analysis of the growth dynamics and toxin production. Three historical clinical isolates (strains1083, 81A330, and 79A292) were obtained from the culture collection at the National Microbiology Laboratory (NML). Two NAP1-related clinical isolates (strains 57A, 83) were provided by Dr. Paul Levett at the Saskatchewan Provincial Health Laboratory. Strains from the American Type Culture Collection included; ATCC 43255, ATCC 43594 (both are toxigenic strains) and ATCC 700057 (non-toxigenic strain).
Polymerase chain reaction and sequencing
PCR was carried out with AmpliTaq Gold in PCR Buffer II (Applied Biosystems) with 0.2 mM dNTPs, 3 mM MgCl2, and various primer concentrations, at an annealing temperature of 58°C. The primers used in this study are listed in Table 1.
Strains were confirmed as C. difficile and putative toxigenic status determined by two PCR multiplexes,  one consisting of the tpi-F/R primers (C. difficile triose phosphate isomerase housekeeping gene) and the tcdA-F/R primers (toxin A), and one consisting of the PaL15/16 primers (tcdC), cdtB-pos/rev primers (binary toxin subunit B), and tcdB-3/4 primers (toxin B).
Genes and flanking regions were amplified for sequence analysis (Table 2) with primers TPR-1/tcdB-UP (tcdR), Lok6/PrimexA (tcdE), and cdd1-A/tcdC3 (tcdC). Oligonucleotides were synthesized, and dideoxy cycle sequencing carried out by the Genomics Core Facility of the NML.
Selective regions of the Toxin A and B were analyzed following  toxinotyping procedure using the B1C and B2N primers to amplify region B1 and A3C and A4N primers to amplify region A3.
Binary toxin PCR was performed following  procedure using the cdtB primers cdtBpos and cdtBrev.
C. difficile strains were grown on Tryptic soy agar containing 5% sheep blood (BA) (Oxoid Nepean, ON) that were incubated at 37°C in a Bactron anaerobic chamber (Sheldon Manufacturing Cornelius, OR). Prior to each experiment, 48 hour pure cultures on BA were subcultured into pre-reduced Brain Heart Infusion broth (BHI) (Difco Kanasas City, MO). After overnight growth at 37°C each culture was used to inoculate BHI (10 mls) or to provide a final bacterial concentration of ~103 cfu/ml. The inoculated BHI culture in Hungate tubes (screw cap with a rubber septum facilitated aspiration of samples) was incubated at 37°C and samples were taken at various time frames over 60 hours to determine viable count and toxin A and B titres using the methods described below.
Samples were serially diluted 1:10 in BHI and then 0.1 ml of each dilution was inoculated onto Clostridium difficile Moxalactam Norfloxacin (CDMN) agar plates (Oxoid Nepean, ON) using the spread plate technique. All counts were performed in triplicate after 48 hours incubation and the average ± standard deviation was determined.
Spores were detected using alcohol shock and quantitative count using the CDMN spread plate technique.
Human foreskin fibroblast (HFF) cells, were used for the Toxin B cytotoxin assay as described by Du et al. . Cells were examined for cytopathic effect (CPE) at 48 hours and a monolayer with at least 50% cell rounding was considered positive for CPE . The titer was reported as the reciprocal of the highest dilution positive for CPE. All results for Toxin B titres were reported as mean ± standard deviation from triplicate experiments. Purified Toxin B (Techlab Blackburg, VA), and myeloma media were included as positive and negative controls respectively. Bartel's (Carlsbad, CA) Toxin B control was also used as a positive control.
The Caco-2 cells (ATCC HTB 37), were maintained and used for the Toxin A tight-junction assay, in Transwell inserts (Corning Costar Corning, NY) as described by Du et al.  as modification of Grasset et al.  method. The transepithelial resistance (TER) was measured using Millicell-ERS (Millipore) and the monolayer was considered to be confluent when the TER was ≥ 400 Ω/cm2 . Samples were considered positive for Toxin A if a 50% drop in resistance was seen within 360 minutes of inoculating the insert. Purified Toxin A, Lot 0195005 (Techlab Blackburg, VA) at 460 ng/ml and cell culture media alone were included as positive and negative controls respectively.
The objective of this study was to evaluate a variety (Figure 1) of clinical strains of C. difficile (NAP1 related and NAP1 non-related) to determine if there was a correlation between the genetic changes detected in the putative negative regulator gene (tcdC) and the growth kinetics and toxin production. The relatedness of strains was assessed by pulsed-field gel electrophoresis (Figure 1) using SmaI as the restriction enzyme following the method of .
The seven strains were assessed to confirm that both Toxin A and B genes were present and to ensure that there were not any large deletions within the B1 or A3 regions [27, 33] of the pathogenicity locus (PaLoc). In addition sequencing was used to evaluate any changes in the positive regulator gene tcdR, the putative toxin secretory gene tcdE, as well as the putative negative regulator gene tcdC. The results of these analyses are shown in Figure 1.
The results of the growth kinetic studies are shown in Figure 2. A clear segregation of strains was observed, as such strains were considered to be high-level producers (HLP) if the titre of Toxin B was ≥ 103 CPE units per ml by 48 hours incubation. The ATCC 43255 strain and the NAP1-related clinical isolates all produced high titres of biologically active Toxin B in broth culture whereas ATCC 43594 and the other three clinical isolates did not. The clinical strain 1083 was the slowest Toxin B producer (Figure 2G) and this was confirmed using multiple repeated growth curves (data not shown).
To determine if these strains had differing levels of biologically active Toxin A production, samples from cultures of each strain under the same growth conditions were evaluated at 24 and 48 hours post-inoculation. The ATCC 43255 strain produced more biologically active Toxin A than any of the other strains when 24 hour cultures were evaluated. By 48 hours (Figure 3), both NAP-related strains (83 and 57A) had reduced the trans-membrane resistance to < 30% whereas this TER was not seen for NAP1-unrelated strains.
Alcohol shock was used to determine what portion of the total viable count was in the spore form (Figure 4). The only major difference in spore formation noted was that strain 43255 had < 1 Log10 of spores after 24 hours incubation whereas all the other strains tested had between 102 to 105 spores/ml. By 48 and 72 hours incubation all strains had ~105 spores/ml from a total population of ~107 cfu/ml (i.e. viable count is predominantly in the vegetative form).
The promoter region of tcdC (-35 to -10 bp upstream of the tcdC gene as described by Hunsdsburger et al. ) was sequenced to determine if the strains evaluated had any differences. An alignment of the sequences showed that all strains had identical promoter sequences (data not shown). Sequencing of the tcdC gene itself demonstrated that there were deletions that would lead to a premature termination codon in the protein sequence that would affect the expected length of the protein product (Figure 1). Alignment of the amino acid sequences is shown in Figure 5. It is apparent that for strains 1083, 57A and 83 that the proteins transcribed and translated from the tcdC gene would be substantially shorter compared to the other strains evaluated that had no deletions or premature stop codons. Although the truncated proteins are somewhat similar in length (63 vs 65 amino acids long), the position of the 1 bp change leads to very different amino acid sequence changes. Strain 1083 has a 1 bp substitution at position 191 that results in a C to A transversion that creates a premature stop codon and results in a 63 amino acid long protein that has an unchanged amino acid sequence up to position 174. Whereas the 1 bp deletion at position 117 in strains 57A and 83 results in a frame shift that leads to an altered amino acid sequence from position 117 onwards and a premature stop codon at positions 187–189 resulting in a predicted product of 65 amino acids.
The sequence analysis of the tcdR genes of the seven strains were identical (data not shown). Sequence analysis of tcdE revealed that only strain 1083 had any deletions. This 1 bp deletion in strain 1083 causes a frame-shift and leads to a stop codon after 18 amino acids compared to expected protein product of 166 amino acids for all other strains (Figure 1).
Because cdtB was detected by PCR, binary toxin was presumed to be produced by the NAP1-related strains 57A and 83 as well as 81A330 and 1083 which are NAP1-unrelated strains by PFGE (Figure 1).
Our results demonstrated that deletions in the tcdC gene cannot be used to predict hyperproduction of Toxin A or B in clinical isolates. Assessment of deletions in this gene could be very misleading if used as a diagnostic approach in patients with CDAD to try to predict who will have more severe disease. Furthermore, our data suggested that tcdC deletions may not be the sole factor responsible for the increased toxin production observed in the NAP-1 isolates. Studies of toxin production using isogenic mutants are warranted to confirm our results.
There are a number of possible explanations for what has been referred to as "hyperproduction" of toxins by some C. difficile strains and not by others. If the positive regulator tcdR was genetically altered in various strains it might result in differing toxin expression between strains. Our sequencing data indicates that the tcdR gene in all strains is identical ruling out genetic differences in the positive regulator gene as an explanation of differences in Toxin A and B production. An alternative mechanism for "hyperproduction" might be that the putative negative regulator tcdC is mutated thereby allowing earlier and more efficient expression of toxin due to the lack of a functional negative regulator. Although there were multiple changes found in tcdC in various strains of C. difficile (e.g. 57A, 83, and 1083) that resulted in predicted truncated proteins that are likely not active, these defects do not always correlate with increased toxin expression. Furthermore, strain ATCC 43255 does not have deletions or mutations in tcdC yet it has the highest levels of Toxin B and Toxin A production in vitro (higher even than the NAP1-related clinical isolates). Strains can differ in the proportion of the population that is in the spore form and this might explain the differences in secreted toxin levels. However, the growth conditions in our study did not result in variation in spore levels for the different strains evaluated. Therefore, the differences in toxin production observed cannot be explained by differences in spore form population. Our data therefore suggest that alterations in the tcdC gene sequence are not accurate predictors of hyper-production of Toxin B or Toxin A.
The ATCC 43255 strain is a known hyperproducer of Toxin B [6, 10, 36] and our data for biologically active toxin production in BHI broth culture support this determination. The use of ATCC 43255 as the "type strain" may be misleading as Warny et al.  assessed 25 Toxinotype 0 clinical isolates (non NAP1-related) and reported that hyperproduction of toxin is not common in non-NAP1 clinical isolates.
The TcdC protein has a predicted transmembrane domain  which was lost for the truncated product and altered amino acid sequence for strains 57A and 83. However, the transmembrane folding motif for TcdC was retained for strain 1083 despite the truncation of this protein. Despite this retained transmembrane motif for strain 1083 it is unlikely that the TcdC protein is fully functional when only a predicted 63 of the total 232 amino acids are present.
Another possible explanation for increased toxin activity in our experiments might be that secretion of the toxins outside the bacterial cell is increased in "hyperproducing" strains. Sequencing of tcdE indicates that there are no differences in this gene in the strains evaluated except for strain 1083 that has a 1 bp deletion that results in a truncated product of 18 amino acids compared to the expected size of 166 amino acids. If secretion was negatively impacted because the TcdE protein product was non-functional (i.e. unable to secrete toxins properly), this might explain why the levels of Toxin B were low in this strain despite the truncation to the tcdC gene that is suspected to predict toxin hyperproduction. Our study evaluated the levels of secreted toxin B, therefore, the levels of toxin detected in our assays would be low if the strain had decreased ability to secrete toxin. However, there are other strains (e.g. 79A292 and 81A330) that are low toxin producers that do not have defects in tcdE. Furthermore, neither ATCC 43255 nor the NAP1-related clinical isolates have defects in tcdE yet they produce high titres of biologically active Toxin B in broth culture.
Our data confirms previous reports [4, 37] as near maximal biologically active Toxin B production was reached earlier in the growth curve (24 hours) of "hyperproducing" strains in BHI compared to "non-hyperproducing" strains (36 to 48 hours). We found that "hyperproducing" strains produced 100 to 1000 fold more Toxin B at 24 and 48 hours in BHI compared to "non-hyperproducing" strains. Our studies focused on biological activity of Toxin A and B whereas, Warny et al.  assessed total protein concentration irrespective of functionality, so this may explain the difference in ratios between "hyperproducing" and "non-hyperproducing" strains. Both studies assessed the culture supernatant from broth cultures as the source of secreted toxin. We used BHI broth and Warny et al.  used an Acambis proprietary broth media, so there may be some differences in the kinetics of toxin production due to different growth medium. In our studies C. difficile strain 43255 produced the highest levels of biologically active Toxin B in BHI broth culture compared to all other strains tested, yet it has no deletions in tcdE, tcdC or tcdR, therefore, our data do not support the conclusion by others [4, 35] that the mutations found in tcdC of NAP1 strains accounts for their higher Toxin B production.
The recent study of Matamouros et al.  used cloning experiments and concluded that tcdR, which is a positive regulator for Toxin A and B production, was under the negative regulatory control of tcdC. They concluded that the TcdC protein product does not directly interact with the Toxin A promoter but rather interacts with TcdR to prevent it from functioning properly and thereby causing a negative impact on Toxin A production (i.e. it acts as a sigma-factor antagonist). They suggest that their data provide the first proof that tcdC is a negative regulator and furthermore, they suggest that epidemic strains have mutations in tcdC that result in hyper-production of toxin. Despite their elegant data to show how TcdR is negatively impacted by TcdC, their data do not provide an explanation for why the C. difficile ATCC strain 43255 is a hyper-producer of Toxins A and B (it has no tcdC mutations and has an intact tcdR). Furthermore, C. difficile strain 1083 has a predicted truncated TcdC yet it does not hyper-produce Toxin A or B. Whether the use of the glutamate dehydrogenase promoter for tcdC in these studies (rather than the actual tcdC promoter) has any role in the finding is unknown (all other genes cloned were under control of their natural promoter) .
The assays used in our study to assess biological activity are different so we cannot directly compare the titres of Toxin B to those of Toxin A. Despite this limitation our data does allow comparison of relative production of each toxin across a range of C. difficile strains. Strain 43255 produced significantly higher titres of biologically active Toxin B and Toxin A in broth culture compared to all other strains. Differences in the binding avidity, or kinetics of glucosyltransferase activity of Toxin A and B was not assessed. Previous studies have reported that mutation of tryptophan-101 in Toxin A (a similar effect was also seen for Toxin B) resulted in reduced glucosyltransferease activity . Our results demonstrated that there was approximately 100–1000-fold higher titres of biologically active Toxin B production after 24 and 48 hours in broth culture for "hyper" versus "non-hyper" producing clinical isolates. Our results were obtained from the analysis of a small number of isolates that were chosen to represent sub-types of C. difficile that have been associated with CDAD. The control strains, ATCC 43255, 43594 and 700057, included the wild-type strain, a second toxigenic strain and a non-toxigenic strain respectively. It is not possible from our data or any of the currently published data to conclusively determine what gene(s) (if any) are responsible for "hyperproduction" of toxins in some strains of C. difficile. Furthermore, the significance of in vitro "hyperproduction" of Toxin A and B may or may not reflect what occurs in vivo. There have been no evaluations of humans infected with "hyperproducing" strains to establish that the titre of Toxin A or B/gram of stool is higher compared to levels in patients infected with non-hyper producing strains of C. difficile. However, the recent study by Freeman et al.  using the human gut model showed that post-exposure to clindamycin, the level of Toxin B production was similar for NAP1-related strain and a ribotype 001 strain.
Our data would suggest that the Caco2 transmembrane resistance assay is an insensitive test method for Toxin A as ≥ 460 ng/ml was needed to give a detectable trans-membrane electrical resistance drop whereas ≥ 150 ng/ml of Toxin B produced detectable CPE in HFF cells. Alternatively Toxin A activity may degrade more rapidly in BHI broth culture compared to Toxin B activity.
In summary, our data do not support the role of mutations in tcdC as the sole basis for NAP1-related strains being hyper-producers of Toxins A and B. The production of isogenic C. difficile mutants has been described by  and this approach may be necessary to clarify the role of tcdC.
Poutanen SM, Simor AE: Clostridium difficile – associated diarrhea in adults. Can Med Assoc J. 2004, 171: 51-58. 10.1503/cmaj.1031189.
Pepin J, Valiquette L, Alary M-E, Villemure P, Pelletier A, Forget K, Pepin K, Chouinard D: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004, 17: 466-472.
Voth DE, Ballard JD: Clostridium difficile Toxins: Mechanism of action and role I disease. Clin Microbiol Rev. 2005, 18: 247-263. 10.1128/CMR.18.2.247-263.2005.
Warny M, Pepin J, Fang A, Killgore G, Thompson A, Brazier J, Frost E, McDonald LC: Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005, 366: 1079-1084. 10.1016/S0140-6736(05)67420-X.
McDonald L, Killgore GE, Thompson A, Owens RC, Kazakova SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005, 353: 2433-2441. 10.1056/NEJMoa051590.
Akerlund T, Svenungsson B, Lagergren A, Burman LG: Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006, 44: 353-358. 10.1128/JCM.44.2.353-358.2006.
Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Micaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczaky Dascal A: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005, 353: 2442-2449. 10.1056/NEJMoa051639.
Pepin J, Valiquette L, Cossette B: Mortality attributable to nosocomial Clostridium difficile-associated disease furing an epidemic caused by a hypervirulent strain in Quebec. CMAJ. 2005, 173: 1-9.
Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M: Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002, 23: 137-140. 10.1086/502023.
Soehn F, Wagenknecht-Wiesner A, Leukel P, Kohl M, Weidmann M, von eichel-Streiber C, Braun : Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864 – implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet. 1998, 258: 222-232. 10.1007/s004380050726.
Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J: Clostridium difficile – associated diarrhea and colitis. Infect Control and Hosp Epidemiol. 1995, 16: 459-477.
Spigaglia P, Mastrantonio P: Comparative analysis of Clostridium difficile clinical isolates belonging to different genetic lineages and time periods. J Med Microbiol. 2004, 53: 1129-1136. 10.1099/jmm.0.45682-0.
Stabler RA, Gerding DN, Songer JG, Drudy D, Brazier JS, Trinh HT, Whitney AA, Hinds J, Wren BW: Comparative phylogenomics of Clostridium difficile reveals clade specificity and microevolution of hypervirulent strains. J Bacteriol. 2006, 188: 7297-7305. 10.1128/JB.00664-06.
Cloud J, Kelly CP: Update on Clostridium difficile associated disease. Current Opinion in Gastroenterology. 2007, 23: 4-9.
Hubert B, Loo VG, Bourgault AM, Poirier L, Dascal A, Fortin E, Dionne M, Lorange M: A portrait of the geographic dissemination of the Clostridium difficile North American Pulsed-Field Type 1 strain and the epidemiology of C. difficile-associated disease in Quebec. CID. 2007, 44: 238-44. 10.1086/510391.
Manitoba Monthly Communicable Disease Report. December 31. 2008, Publisher: Public Health Division, Public Health, Winnipeg, MB, Canada, [http://www.gov.mb.ca/health/publichealth/cdc/surveillance/index.html#reports]
Chernak E, Johnson CC, Weltman A, Wiggs L, Killgore G, Thompson A, LeMaile-Williams M, Lewis FM: Severe Clostridium difficile-associated disease in populations previously at low risk – Four States 2005. MMWR. 2005, 54: 1201-1205.
Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S: Distribution of Clostridium difficile variant toxintypes and strains with binary toxin genes among clinical isolates in an American hospital. J MedMicrobiol. 2004, 53: 887-894.
Geric B, Johnson S, Gerding DN, Brabnar M, Rupnik M: Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol. 2003, 41 (11): 5227-5232. 10.1128/JCM.41.11.5227-5232.2003.
MacCannell DR, Louie TJ, Gregson DB, Laverdiere M, Labbe A-C, Laing F, Henwick S: Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006, 44: 2147-2152. 10.1128/JCM.02563-05.
Stare B, Delmee M, Rupnik M: Variant Forms of the binary toxin CDT locus and tcdC gene in Clostridium difficile strains. J Med Microbiol. 2007, 56: 329-335. 10.1099/jmm.0.46931-0.
Chang S-Y, Song K-P: ADP-riobsylating binary toxin genes of Clostridium difficile strain CCUG 20309. DNA Sequence. 2001, 12: 115-120. 10.3109/10425170109047564.
Goncalves C, Decre D, Barbut F, Burghoffer B, Petit J-C: Prevalence and characterization of a binary toxin (Actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004, 42: 1933-1939. 10.1128/JCM.42.5.1933-1939.2004.
Terhes G, Urban E, Soki J, Hamid KA, Nagy E: Community-acquired Clostridium difficile diarrhea caused by binary toxin, Toxin A and Toxin B gene-positive isolates in Hungary. J Clin Microbiol. 2004, 42: 4316-4318. 10.1128/JCM.42.9.4316-4318.2004.
Spigaglia P, Mastrantonio P: Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 2002, 40: 3470-3475. 10.1128/JCM.40.9.3470-3475.2002.
Lemee L, Dhalluin A, Testelin S, Mattrat M.-A, Maillard K, Lemeland J-F, Pons J-L: Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (toxin A), and tcdB (toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol. 2004, 42: 5710-5714. 10.1128/JCM.42.12.5710-5714.2004.
Rupnik M, Dupuy B, Fairweather NF, Gerding DN, Johnson S, Just I, Lyerly DM, Popoff MR, Rood JI, Sonenshein AL, Thelestam M, Wren BW, Wilkins TD, von Eichel-Streiber C: Revised nomenclature of Clostridium difficile toxins and associated genes. J Med Microbiol. 2005, 54: 113-117. 10.1099/jmm.0.45810-0.
Stubbs S, Rupnik M, Gibert M, Brazier J, Duerden B, Popoff M: Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiology Letters. 2000, 186: 307-312. 10.1111/j.1574-6968.2000.tb09122.x.
Alfa MJ, Swan B, VanDekerkhove B, Pang P, Harding GKM: The diagnosis of Clostridium difficile-associated diarrhea: comparison of Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays. Diagnostic Microbiology and Infectious Disease. 2002, 43: 257-263. 10.1016/S0732-8893(02)00413-3.
Du T, Alfa MJ: Translocation of Clostridium difficile toxin B across polarized Caco-2 cell monolayers is enhanced by toxin A. Canadian Journal of Infectious Disease. 2004, 15: 2-
Grasset E, Pinto M, Dussaulx E, Zweibaum A, Desjeux J: Epithelial properties of human colonic carcinoma cell line Caco-2: Electrical parameters. Am J Physiol. 1984, 247: C260-7.
Alfa MJ, Kabani A, Lyerly D, Moncrief S, Neville LM, Al-Barrak A, Harding GKH, Dyck B, Olekson K, Embil JM: Characterization of a toxin A-negative, toxinB-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol. 2000, 38: 2706-2714.
Rupnick M, Braun V, Soehn F, Janc M, Hofsetter M, Laufenberg-Feldmann R, von Eichel-Streiber C: Characterization of polymprphisms in the toxin A and B genes of Clostridium difficile. FEMS Microbiology Letters. 1997, 148: 197-202. 10.1111/j.1574-6968.1997.tb10288.x.
Hundsberger T, Braun V, Weidmann M., Leukel P, Sauerborn M, von Eichel-Streiber C: Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem. 1997, 244 (3): 735-742. 10.1111/j.1432-1033.1997.t01-1-00735.x.
Curry SR, March JW, Muto CA, O'Leary MM, Pasculle AW, Harrison LH: tcdC Genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007, 45: 215-221. 10.1128/JCM.01599-06.
Karlsson S, Dupuy B, Mukherjee K, Norin E, Burman Lars G, Akerlund T: Expression of Clostridium difficile Toxins A and B and their Sigma Factor TcdD is controlled by temperature. Infect Immun. 2003, 71: 1784-1793. 10.1128/IAI.71.4.1784-1793.2003.
Matamouros S, England P, Dupuy B: Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol. 2007, "Postprint;" doi: 10:1111/j.1365-2958.2007.05739.x.
Teichert M, Tatge H, Schoentaube J, Just I, Gerhard R: Application of mutated Clostridium difficile Toxin a for determination of glycosyltransferase-dependent effect. Infect Immun. 2006, 74: 6006-6010. 10.1128/IAI.00545-06.
Freeman J, Baines SD, Saxton K, Wilcos MH: Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 01 and 027 in a human gut model. J Antimicrobial Chemotherapy. 2007
O'Connor JR, Lyras D, Farrow KA, Adams V, Powell DR, Hinds J, Cheung JK, Rood JI: Construction and analysis of chromosomal Clostridium difficile mutants. Molec Microbiol. 2006, 61: 1335-1351. 10.1111/j.1365-2958.2006.05315.x.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/9/103/prepub
The skilled technical assistance of the Microbiology Department.
The authors declare that they have no competing interests.
All authors read and approved the final manuscript. MA contributed to the conceptual design, data analysis and writing. RM contributed to the conceptual design, data analysis and writing. PL contributed to the data analysis, writing, and experimental testing. DB contributed to the experimental testing (PCR & PFGE) and writing. MM contributed to the data analysis and writing.
Ruth Murray, Dave Boyd, Paul N Levett, Michael R Mulvey contributed equally to this work.
About this article
Cite this article
Murray, R., Boyd, D., Levett, P.N. et al. Truncation in the tcdC region of the Clostridium difficilePathLoc of clinical isolates does not predict increased biological activity of Toxin B or Toxin A. BMC Infect Dis 9, 103 (2009). https://doi.org/10.1186/1471-2334-9-103
- Clinical Isolate
- Brain Heart Infusion
- Toxin Production
- Triose Phosphate Isomerase
- Active Toxin